EMEA: Guideline on the Clinical investigation of recombinant and human plasma-derived factor IX products

This guideline describes the information to be documented when an application for a marketing authorisation for recombinant or plasma-derived factor IX products is made for use in treatment and prevention of bleeding in patients with haemophilia B. The guideline covers clinical investigations to be conducted pre- and post-marketing authorisation. The guideline is also provided for authorised products where a significant change in the manufacturing process has been made.